Article
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Oncotarget - 4 Jul 2017
Yeh Chun-Nan, Chen Ming-Huang, Chen Yen-Yang, Yang Ching-Yao, Yen Chueh-Chuan, Tzen Chin-Yuan, Chen Li-Tzong, Chen Jen-Shi
Abstract excerpt
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are caused by the constitutive activation of KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations. Imatinib selectively inhibits KIT and PDGFR, leading to disease control for 80%-90% of patients with metastatic GIST. Imatinib resistance can occur within a median of 2-3 years due to secondary mutations in KIT. According to preclinical studies,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.